Organization
Veneto Institute of Oncology IOV–IRCCS
7 abstracts
Abstract
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.Org: Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Veneto Institute of Oncology IOV–IRCCS, Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Ospedale Santa Maria delle Croci,
Abstract
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, Digestive Oncology Department, APHP.Centre - Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT).Org: University of Pisa, Pisa, Italy, Azienda Ospedaliero-Universitaria Pisana, Vall d’Hebron Institute of Oncology (VHIO), Veneto Institute of Oncology IOV–IRCCS, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.Org: Medical Oncology 1, Venetian Institute of Oncology-IRCCS, Padua, Padua, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Department of Medicine (DIMED) University of Padua and Veneto Institute of Oncology (IOV-IRCCS ),
Abstract
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067.Org: Dana-Farber Cancer Institute, Veneto Institute of Oncology IOV–IRCCS, University of Colorado Cancer Center, Aix-Marseille University CHU Timone, Maria Skłodowska-Curie National Institute of Oncology Center,
Abstract
Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA1/2 (gBRCA) mutations.Org: University of Verona, Oncology Section, Verona University Hospital Trust (AOUI Verona), IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele Facoltà di Medicina e Chirurgia, University of Bologna,
Abstract
NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.Org: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Department of Medical and Surgical Specialties,